Trial Profile

A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Porgaviximab (Primary) ; Antivirals
Indications Ebola virus infections
Focus Therapeutic Use
Acronyms PREVAIL II

Most Recent Events

23 May 2019 Status changed from discontinued to completed.
12 Jun 2018 Planned End Date (expected follow-up date for patients receiving therapy after the trial is discontinued) changed from 31 Dec 2018 to 1 Jan 2021.
13 Oct 2016 Results published in the New England Journal of Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com